UNSPSC 51312313: Diphenhydramine salicylate

This classification denotes a histamine-1 receptor antagonist and antiemetic agent with the molecular formula C17H21NO.C7H6O3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 707L3YC54L, chemically known as 2-(diphenylmethoxy)-n,n-dimethylethylamine hydrochloride but more generally known as diphenhydramine salicylate, which bears US NIH Compound Identifier 3100. European Medicines Agency schedules Diphenhydramine salicylate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB01774MIG.

Most nations, for tariff and trade purposes, schedule diphenhydramine salicylate under HS 29221980 and SITC 51461. As of Q4 2014, DIPHENHYDRAMINE SALICYLATE remains US FDA's Preferred Term for this commodity. SMILES: CN(C)CCOC(C1CCCCC1)C2CCCCC2.C1CCC(C(C1)C(=O)O)O.

UNSPSC 51312313 Diphenhydramine salicylate is a Commodity code that in practice covers pharmaceutical products and over-the-counter medications purchased through state and local procurement channels, though recent solicitations show limited activity specifically under this narrow product code. State and local governments use related codes to procure generic pharmaceuticals, branded medications, naloxone and other emergency response drugs, and OTC products through competitive bidding, cooperative purchasing agreements, and request-for-information processes. Issuing bodies include county health departments, state health and human services agencies, and multistate cooperative purchasing alliances administering on behalf of participating state and local governments. The work involves manufacturer supply agreements, wholesaler distribution arrangements, product compliance certification, and fixed or negotiated pricing models.

Recent activity spans Florida, Texas, and Minnesota. Seminole County, Florida issued IFB 60459723LAS in June 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries and a two-year initial term plus one-year renewal option; response deadline was July 26, 2023. The Texas Health and Human Services Commission posted RFI HHS0017013 in April 2026 to gather vendor capabilities on direct-to-manufacturer prescription programs outside traditional pharmacy benefit manager and group purchasing organization channels. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed through three authorized wholesalers across participating state and local government facilities including Oregon, with proposals due March 26, 2026 and contract effectiveness July 1, 2026.